Please wait a minute...
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2017, Vol. 18 Issue (1): 27-36    DOI: 10.1631/jzus.B1600205
Articles     
Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells
Zhong-dong Wang, Fan-yong Qu, Yuan-yuan Chen, Zhang-shen Ran, Hai-yan Liu, Hai-dong Zhang
Clinical Laboratory of Taishan Sanatorium of Shandong Province, Tai'an 271001, China; Interventional Radiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264100, China; Center of Health Examination, Affiliated Hospital of Taishan Medical University, Tai'an 271001, China; Department of Oncology, Affiliated Hospital of Taishan Medical University, Tai'an 271001, China; Department of Basic Medicine, Taishan Medical University, Tai'an 271001, China
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Objective: Hepatocellular carcinoma (HCC) is still one of the most common death-related malignancies worldwide. Because the way onset and progression are hidden most, HCC diagnoses are made at an advanced stage, when they are unsuitable for surgical resection. MicroRNAs are a class of small non-coding RNAs, participating in many aspects of cancers. In this study, we tried to establish the role of microRNA-718 (miR-718) in the malignant phenotype of HCC cells and its possible role in HCC diagnosis. Methods: Here we first used a methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, Transwell migration and invasion assays, and colony formation assay to evaluate the impact of miR-718 on the malignant phenotypes of HCC cells. Then, we used bioinformatic methods to predict the target gene of miR-718 and used green fluorescence protein (GFP) reporter assay, Western blot, and quantitative real-time polymerase chain reaction (qRT-PCR) to validate the regulation relationship. Finally, we determined the role of the target gene in the HCC phenotype. Results: We found that the expression of miR-718 was significantly reduced in various HCC cell lines and HCC tissues. Re-expression of miR-718 significantly reduced the cellular viability and colony formation ability as well as inhibited the migration and invasion abilities of HCC cell lines. Early growth response protein 3 (EGR3) is a direct target of miR-718 and is negatively regulated by miR-718. EGR3 could increase the viability and proliferation of HCC cells, and promot the migration and invasion of HCC cells. Conclusions: miR-718 acts as a tumor suppressive microRNA in HCC via regulating the expression of EGR3, which may provide a new diagnostic marker and treatment target for HCC.

Key wordsmiR-718      MicroRNA      Early growth response protein 3 (EGR3)      Hepatocellular carcinoma (HCC)      Malignant phenotype     
Received: 10 May 2016      Published: 03 January 2017
CLC:  R735.2  
Cite this article:

Zhong-dong Wang, Fan-yong Qu, Yuan-yuan Chen, Zhang-shen Ran, Hai-yan Liu, Hai-dong Zhang. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 27-36.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.B1600205     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2017/V18/I1/27

[1] Ri-sheng Que, Cheng Lin, Guo-ping Ding, Zheng-rong Wu, Li-ping Cao. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pancreatic cancer[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2016, 17(5): 352-360.
[2] Bin Xu, Yao-yao Li, Jun Ma, Fu-xing Pei. Roles of microRNA and signaling pathway in osteoarthritis pathogenesis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2016, 17(3): 200-208.
[3] Chen Chen, Yang-yang Fan, Xin Wang, Fei Song, Tao Jiang, Ping Qian, Shun-Ming Tang, Xing-Jia Shen. bmo-miR-0001 and bmo-miR-0015 down-regulate expression of Bombyx mori fibroin light chain gene in vitro[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2016, 17(2): 127-135.
[4] Wei Wang, Yun-ping Luo. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2015, 16(1): 18-31.
[5] Ying-li Lu, Wen Jing, Lian-shi Feng, Li Zhang, Jian-fang Xu, Tong-jian You, Jing Zhao. Effects of hypoxic exercise training on microRNA expression and lipid metabolism in obese rat livers[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(9): 820-829.
[6] Zhen Dai, Rong Wu, Yi-cheng Zhao, Kan-kan Wang, Yong-ye Huang, Xin Yang, Zi-cong Xie, Chang-chun Tu, Hong-sheng Ouyang, Tie-dong Wang, Da-xin Pang. Early lethality of shRNA-transgenic pigs due to saturation of microRNA pathways[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(5): 466-473.
[7] Zi-ming Yuan, Zhi-li Yang, Qi Zheng. Deregulation of microRNA expression in thyroid tumors[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(3): 212-224.
[8] Yi-qiang Han, Zheng Hu, Dian-feng Zheng, Ya-mei Gao. Analysis of promoters of microRNAs from a Glycine max degradome library[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(2): 125-132.
[9] Quan-wu Zhu, Yao-ping Luo. Identification of miRNAs and their targets in tea (Camellia sinensis)[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2013, 14(10): 916-923.
[10] Yue Zhang, Ying-ke Li. MicroRNAs in the regulation of immune response against infections[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2013, 14(1): 1-7.
[11] Shailendra Kapoor. Curcumin and its emerging intraocular benefits[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2013, 14(1): 85-86.
[12] Yong-fang JIANG, Jing MA, Yan HE, Yong-hong ZHANG, Yun XU, Guo-zhong GONG. Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2009, 10(1): 7-13.
[13] WU Xiao-mo, FU Jing-geng, GE Wang-zhong, ZHU Jiang-yan, WANG Jun-yong, ZHANG Wei, QIAN Wei, HUO Ke-ke. Screen p53 mutations in hepatocellular carcinoma by FASAY: A novel splicing mutation[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2007, 8(2): 81-87.